Results 171 to 180 of about 30,927 (236)

Move along, nothing to see here: Btk inhibitors stop platelets sticking to plaques [PDF]

, 2018
Busygina, Bye, Bye, Byrd, Jamasbi, Levade   +5 more
core   +1 more source

First Line Therapy in Mantle Cell Lymphoma-The Role of BTKi in the Initial Treatment of Transplant-Eligible and -Ineligible Patients. [PDF]

Hematol Oncol
Silkenstedt E, Dreyling M.
europepmc   +1 more source

ATM inhibition decreases ERK activation and is synergistic with ibrutinib in primary chronic lymphocytic leukemia cells. [PDF]

Blood Adv
Kost SEF, Saleh A, Brown J, Yuan SH, Kuzio B, Yang L, Banerji V, Gibson SB, Johnston JB, Katyal S.   +9 more
europepmc   +1 more source

Expression of HERV-K and embryonic genes in chronic lymphocytic leukemia and their association with therapy regimens. [PDF]

Blood Adv
Matteucci C, Petrone V, Giovinazzo A, Laureana R, Postorino M, Pupo L, Cipriani C, Toschi N, Fanelli M, Minutolo A, Paterno G, Buzzatti E, Sinibaldi Vallebona P, Zucchetto A, Pozzo F, Gattei V, Del Poeta G, Venditti A, Balestrieri E, Del Principe MI.   +19 more
europepmc   +1 more source

Ibrutinib-Induced Perianal Rash Complicated by Bacterial Infection in a Patient With Chronic Lymphocytic Leukemia: A Case Report and Literature Review. [PDF]

Cureus
Singh J, Gupta P, Vargas J, Kudelka A, Kobe M, Rocca N.   +5 more
europepmc   +1 more source

Immunohistochemical Study of the Localization of Ibrutinib-Protein Conjugates in the Rat Gastrointestinal Tract. [PDF]

Acta Histochem Cytochem
Kataoka H, Saita T, Yamamoto Y, Kimura S, Sogawa R, Shimanoe C.   +5 more
europepmc   +1 more source

Faculty Opinions recommendation of Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

, 2017
Varsha Gandhi, Prithviraj Bose
openalex   +2 more sources

A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases. [PDF]

J Comp Eff Res
Rogers KA, Muluneh B, Qureshi ZP, He J, Bokun A, Ding Z, Lafeuille MH, Gogna P, Emond B, Fradley M.   +9 more
europepmc   +1 more source

Advancing Mantle Cell Lymphoma Risk Assessment: Navigating a Moving Target. [PDF]

Hematol Oncol
Ferrero S, Ragaini S.
europepmc   +1 more source

GPR83 protects cochlear hair cells against ibrutinib-induced hearing loss through AKT signaling pathways. [PDF]

Front Med (Lausanne)
Zhang Y, Xiao Y, Zhu Y, Yan L, Cheng N, Wei Y, Zhang Y, Tian Y, Cao W, Yang J.   +9 more
europepmc   +1 more source